Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Inhaled Treprostinil in Pulmonary Arterial Hypertension
NCT01557647Phase 3Withdrawn
- Sponsor
- United Therapeutics Corporation
- Start
- Jun 2012
- Primary completion
- Dec 2015
- Modality
- Orthosteric Ligands
01
Overview
A Phase 3 trial of treprostinil in pulmonary arterial hypertension (PAH), sponsored by United Therapeutics Corporation. Planned start Jun 2012; status: withdrawn.
02
Drugs
treprostinil
03
Conditions
pulmonary arterial hypertension (PAH)
Beyond the preview
Go deeper on NCT01557647.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01557647.